Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

 
The Bastide Group enters the respiratory care devices market in Italy
The Bastide Group enters the respiratory care devices market in Italy

Caissargues, July 18, 2022

The Bastide Group announces the acquisition of a majority stake in Oxystore, a company based near Milan, Italy. Oxystore specializes in home diagnosis and online sales of

 
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed
BASTIDE : Acceleration in growth in the third quarter, to 6% - Outlook confirmed

Caissargues, May 12, 2022

 

In €k 2020-2021 2021-2022 Change 3rd quarter revenue 111,669 118,446 +6.1% 9-month revenue 333,033 341,491 +2.5%

 

 

Group

The Non-Financial Rating Agency Vigeo-Eiris Classifies Korian 1st Company in the Healthcare Sector for its ESG1 Commitments
The Non-Financial Rating Agency Vigeo-Eiris Classifies Korian 1st Company in the Healthcare Sector for its ESG1 Commitments


Korian (Paris:KORI), the leading European care services company for elderly and fragile people, welcomes the report published early October by the non-financial rating agency Vigeo-Eiris (V.E), a

Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021


Regulatory News:



Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)

BIOCORP und NOVO NORDISK schließen weltweite Partnerschaft im Bereich Diabetes und digitale Gesundheit : https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP und NOVO NORDISK schließen weltweite Partnerschaft im Bereich Diabetes und digitale Gesundheit


BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen

BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health


Regulatory News:



BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today

BIOCORP und MERCK unterzeichnen Kooperationsvereinbarung auf dem Gebiet des menschlichen Wachstumshormons (HGH): https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP und MERCK unterzeichnen Kooperationsvereinbarung auf dem Gebiet des menschlichen Wachstumshormons (HGH)


Aufsichtsrechtliche Meldungen:



BIOCORP (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen

BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone (HGH): https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone (HGH)


Regulatory News:



BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck, a leading

EOS imaging Reports its Full Year 2020 Results and First Quarter 2021 Revenues
EOS imaging Reports its Full Year 2020 Results and First Quarter 2021 Revenues


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

BIOCORP und ROCHE DIABETES CARE FRANCE bringen Mallya auf den Markt – das innovative medizinische Gerät verbessert die Lebensqualität von Diabetes-Patienten: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP und ROCHE DIABETES CARE FRANCE bringen Mallya auf den Markt – das innovative medizinische Gerät verbessert die Lebensqualität von Diabetes-Patienten


Pflichtmitteilung:



BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf Design, Entwicklung und Herstellung von innovativen

BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes


Regulatory News:



BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME) , a French company specialized in the design, development and manufacturing of innovative medical devices, and

BIOCORP unterzeichnet zwei neue Vereinbarungen zur Nutzung von Mallya-Technologie: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP unterzeichnet zwei neue Vereinbarungen zur Nutzung von Mallya-Technologie


BIOCORP (FR0012788065 - ALCOR / PEA/KMU-qualifiziert) (Paris:ALCOR), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen

BIOCORP Signs Two New Partnerships With Mallya Technology: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP Signs Two New Partnerships With Mallya Technology


Regulatory News:



BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today

EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year
EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

EOS imaging Announces Its Financial Agenda For 2021
EOS imaging Announces Its Financial Agenda For 2021


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”


Regulatory News:



Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna

Mauna Kea Technologies Announces Two New Publications Demonstrating the Efficacy, Safety and Accuracy of Cellvizio® for Pancreatic Cyst Evaluation
Mauna Kea Technologies Announces Two New Publications Demonstrating the Efficacy, Safety and Accuracy of Cellvizio® for Pancreatic Cyst Evaluation


Regulatory News:



Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE)

EOS imaging Reports 9-month Revenue up +32% Year-on-year
EOS imaging Reports 9-month Revenue up +32% Year-on-year


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

EOS imaging: First EOSedge™ Installation in Australia
EOS imaging: First EOSedge™ Installation in Australia


EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announces the

EOS imaging: First EOSedgeTM Installation in Australia
EOS imaging: First EOSedgeTM Installation in Australia


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

MEDICREA Reports Third Quarter 2020 Sales
MEDICREA Reports Third Quarter 2020 Sales


The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

BIOCORP meldet Partnerschaft mit der AARDEX Group zur Erweiterung intelligenter Lösungen für eine präzise Medikamentenadhärenz: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP meldet Partnerschaft mit der AARDEX Group zur Erweiterung intelligenter Lösungen für eine präzise Medikamentenadhärenz


BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen

BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence: https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg
BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence


Regulatory News:



BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today

EOS imaging Reports Its 2020 Half-year Financial Results
EOS imaging Reports Its 2020 Half-year Financial Results


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

MEDICREA Reports First Half 2020 Results
MEDICREA Reports First Half 2020 Results


The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling